New drug FSD201 tested for mysterious chronic pain condition
Symptom relief
Terminated
This study tested whether FSD201 can reduce daily pain in adults with chronic widespread pain caused by idiopathic mast cell activation syndrome (MCAS). Only 2 people enrolled before the study ended early. Participants took FSD201 or a placebo for 56 days, and pain was measured u…
Phase: PHASE2 • Sponsor: Quantum Biopharma • Aim: Symptom relief
Last updated May 26, 2026 10:24 UTC